Evidence map›Paper›PMID 30188957›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2018

Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction.

Stephan von Haehling, Jan Bělohlávek, Fikret Er, Natig Gassanov, Fabio Guarracino, Olivier Bouvet

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting.European heart journal supplements : journal of the European Society of Cardiology · 2018
    Article
  10. Landiolol for managing atrial fibrillation in intensive care.European heart journal supplements : journal of the European Society of Cardiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Stephan von HaehlingDepartment of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Strasse 40, Göttingen, Germany.
Jan BělohlávekDepartment of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital and 1st Faculty of Medicine, Charles University, U Nemocnice 2, Praha 2, Prague, Czech Republic.
Fikret ErDepartment of Cardiology, Rhythmology and Intensive Care Medicine, Klinikum Gütersloh, Germany.
Natig GassanovDepartment of Cardiology, Rhythmology and Intensive Care Medicine, Klinikum Gütersloh, Germany.
Fabio GuarracinoDepartment of Anaesthesia and Critical Care Medicine, Cardiothoracic and Vascular Anaesthesia, Azienda Ospedaliero Universitaria Pisana, Via Roma n. 67, Pisa, Italy.
Olivier BouvetDepartment of Clinical Research and Pharmaceutical Development, Amomed Pharma GmbH Vienna, Austria.
Azienda Ospedaliera Universitaria Pisana · ITCharles University · CZUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodynamics. Landiolol is an injectable ultra-short beta-blocker with very high beta-1 selectivity, listed in Japanese Guidelines for AFib management as potential option for rate control of patient with heart failure. Landiolol is now available in Europe with indication of controlling heart rate in AFib and supraventricular tachycardia. This review discusses existing clinical data in Japan and perspectives of landiolol use for acute rate control of AFib patients with cardiac dysfunction.

Indexed as

Atrial fibrillationBeta-blockersHeart failureLandiololSupraventricular tachycardia

Identifiers

PMID30188957
PMCPMC5909772
OpenAlexW2782873935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.